Lilly's revenue soars 48%, driven by demand of its GLP-1s

Market Watch News Agency

Yesterday•Market Watch

General Medium Importance Neutral

Lilly's revenue soars 48%, driven by demand of its GLP-1s

Its sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Source: Market Watch

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category General

Source Market Watch

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #837

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

Lilly's revenue soars 48%, driven by demand of its GLP-1s

Comments

User Menu